BRIEF-Revolution Medicines And Summit Therapeutics Enter Into Clinical Collaboration To Evaluate Combinations Of Three Ras(On) Inhibitors With Ivonescimab In Ras Mutant Tumors

Reuters

Jun 30, 2025

BRIEF-Revolution Medicines And Summit <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Enter Into Clinical Collaboration To Evaluate Combinations Of Three Ras(On) Inhibitors With Ivonescimab In Ras Mutant Tumors

Revolution Medicines Inc RVMD.O:

REVOLUTION MEDICINES AND SUMMIT THERAPEUTICS ENTER INTO CLINICAL COLLABORATION TO EVALUATE COMBINATIONS OF THREE RAS$(ON)$ INHIBITORS WITH IVONESCIMAB IN RAS MUTANT TUMORS
REVOLUTION MEDICINES INC - SUMMIT TO SUPPLY IVONESCIMAB, REVOLUTION MEDICINES TO SPONSOR STUDY

Source text: ID:nGNX8PWjNv

Further company coverage: RVMD.O

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2547099244"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2547099244\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2547099244?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-30 20:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2547099244","market":"us","top_or_hot":-1,"title":"BRIEF-Revolution Medicines And Summit Therapeutics Enter Into Clinical Collaboration To Evaluate Combinations Of Three Ras(On) Inhibitors With Ivonescimab In Ras Mutant Tumors","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Revolution Medicines And Summit <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Enter Into Clinical Collaboration To Evaluate Combinations Of Three Ras(On) Inhibitors With Ivonescimab In Ras Mutant Tumors</title></head><body><p>Revolution Medicines Inc <span>RVMD.O</span>:</p><ul><li><p>REVOLUTION MEDICINES AND SUMMIT THERAPEUTICS ENTER INTO CLINICAL COLLABORATION TO EVALUATE COMBINATIONS OF THREE RAS<a href=\"https://laohu8.com/S/ON\">$(ON)$</a> INHIBITORS WITH IVONESCIMAB IN RAS MUTANT TUMORS</p></li><li><p>REVOLUTION MEDICINES INC - SUMMIT TO SUPPLY IVONESCIMAB, REVOLUTION MEDICINES TO SPONSOR STUDY</p></li></ul><p>Source text: <span>ID:nGNX8PWjNv</span></p><p>Further company coverage: <span>RVMD.O</span></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Revolution Medicines And Summit Therapeutics Enter Into Clinical Collaboration To Evaluate Combinations Of Three Ras(On) Inhibitors With Ivonescimab In Ras Mutant Tumors</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Revolution Medicines And Summit Therapeutics Enter Into Clinical Collaboration To Evaluate Combinations Of Three Ras(On) Inhibitors With Ivonescimab In Ras Mutant Tumors\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-30 20:15</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Revolution Medicines And Summit <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Enter Into Clinical Collaboration To Evaluate Combinations Of Three Ras(On) Inhibitors With Ivonescimab In Ras Mutant Tumors</title></head><body><p>Revolution Medicines Inc <span>RVMD.O</span>:</p><ul><li><p>REVOLUTION MEDICINES AND SUMMIT THERAPEUTICS ENTER INTO CLINICAL COLLABORATION TO EVALUATE COMBINATIONS OF THREE RAS<a href=\"https://laohu8.com/S/ON\">$(ON)$</a> INHIBITORS WITH IVONESCIMAB IN RAS MUTANT TUMORS</p></li><li><p>REVOLUTION MEDICINES INC - SUMMIT TO SUPPLY IVONESCIMAB, REVOLUTION MEDICINES TO SPONSOR STUDY</p></li></ul><p>Source text: <span>ID:nGNX8PWjNv</span></p><p>Further company coverage: <span>RVMD.O</span></p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2488822045.USD","symbol_name":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250630:nTUANYMWB:1","article_id":"2547099244","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2547099244","pubTimestamp":1751285717,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Revolution Medicines And Summit Therapeutics Enter Into Clinical Collaboration To Evaluate Combinations Of Three Ras(On) Inhibitors With Ivonescimab In Ras Mutant TumorsRevolution Medicines Inc ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","BK4139":"生物科技","SMMT":"Summit Therapeutics PLC","RVMD":"Revolution Medicines, Inc."},"translate_title":"BRIEF-Revolution Medicines和Summit Therapeutics开展临床合作，评估三种Ras(On)抑制剂与Ivonescimab联合治疗Ras突变肿瘤","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMT":0.9,"RVMD":0.9},"content_text":"BRIEF-Revolution Medicines And Summit Therapeutics Enter Into Clinical Collaboration To Evaluate Combinations Of Three Ras(On) Inhibitors With Ivonescimab In Ras Mutant TumorsRevolution Medicines Inc RVMD.O:REVOLUTION MEDICINES AND SUMMIT THERAPEUTICS ENTER INTO CLINICAL COLLABORATION TO EVALUATE COMBINATIONS OF THREE RAS$(ON)$ INHIBITORS WITH IVONESCIMAB IN RAS MUTANT TUMORSREVOLUTION MEDICINES INC - SUMMIT TO SUPPLY IVONESCIMAB, REVOLUTION MEDICINES TO SPONSOR STUDYSource text: ID:nGNX8PWjNvFurther company coverage: RVMD.O","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}